Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Analgesia and Pain Management

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...

Peripheral Artery Disease V: Postoperative Nursing Management

Peripheral Artery Disease V: Postoperative Nursing Management

During the postoperative period, it is crucial to focus on maintaining circulation, identifying and managing potential complications, and planning for discharge.Nursing AssessmentVital signs monitoring: Regularly monitor vital signs, including blood pressure, heart rate, respiratory rate, and temperature, to detect early signs of complications such as bleeding and infection.Circulation assessment: Monitor pulses, perform Doppler assessments, and check capillary refill, color, temperature, and...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Consistent sex-dependent effects of PKMζ gene ablation and pharmacological inhibition on the maintenance of referred pain.

Molecular pain·2016

Same author

Effects of topical combinations of clonidine and pentoxifylline on capsaicin-induced allodynia and postcapsaicin tourniquet-induced pain in healthy volunteers: a double-blind, randomized, controlled study.

Pain·2016

Same author

Topical combinations to treat microvascular dysfunction of chronic postischemia pain.

Anesthesia and analgesia·2014

Same author

Neuropathic pain: strategies in drug discovery and treatment.

Expert opinion on drug discovery·2013

Same author

Topical combinations aimed at treating microvascular dysfunction reduce allodynia in rat models of CRPS-I and neuropathic pain.

The journal of pain·2013

Same author

Systemic pregabalin attenuates sensorimotor responses and medullary glutamate release in inflammatory tooth pain model.

Neuroscience·2012

Search research articles

Related Experiment Video

Updated: May 9, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Pentoxifylline reduces chronic post-ischaemia pain by alleviating microvascular dysfunction.

J Vaigunda Ragavendran¹, A Laferrière, M Khorashadi

¹Department of Anesthesia, McGill University, Montreal, Canada; Alan Edwards Centre for Research on Pain, McGill University, Montreal, Canada.

European Journal of Pain (London, England)

|August 2, 2013

Summary

Pentoxifylline (PTX) alleviates chronic post-ischaemia pain (CPIP) and associated allodynia in rats by improving early microvascular dysfunction. However, PTX loses effectiveness in later stages of CPIP.

Related Experiment Videos

Last Updated: May 9, 2026

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Published on: June 29, 2013

Area of Science:

Pain research
Vascular biology
Pharmacology

Background:

Microvascular dysfunction and muscle ischemia contribute to cutaneous tactile allodynia in chronic post-ischaemia pain (CPIP).
Pentoxifylline (PTX), a vasodilator and haemorrheologic agent, was investigated for its potential to alleviate allodynia in CPIP by addressing microvascular dysfunction.

Purpose of the Study:

To assess if pentoxifylline (PTX) can relieve allodynia in chronic post-ischaemia pain (CPIP) rats.
To determine if PTX alleviates microvascular dysfunction contributing to CPIP.

Main Methods:

Laser Doppler flowmetry measured plantar blood flow to assess PTX effects on post-occlusive reactive hyperaemia (microvascular function).
Von Frey testing evaluated PTX's efficacy against CPIP-induced allodynia.
Time-course studies assessed PTX effects early (2-8 days) and late (18-25 days) post-ischaemia/reperfusion (I/R) injury.

Main Results:

PTX (25 mg/kg) demonstrated significant anti-allodynic effects up to 21 days post-I/R injury, but was ineffective at 30 days.
PTX significantly improved reduced reactive hyperaemia in early CPIP rats, indicating improved microvascular function.
PTX did not affect reactive hyperaemia in late CPIP rats, as pre-drug hyperaemia was not significantly reduced in these animals.

Conclusions:

The anti-allodynic effect of PTX in early CPIP may stem from its ability to ameliorate microvascular dysfunction.
Poor tissue perfusion is implicated in the early stages of CPIP pain.
These findings suggest PTX's therapeutic potential in models of complex regional pain syndrome type I, particularly in early disease stages.